- Published on
Dermatology - Junctional Hereditary Epidermolysis Bullosa
Hereditary epidermolysis bullosa refers to a range of uncommon genetic skin disorders. Disruption of the structural integrity of the outermost layer of skin (epidermis) and/or the layer beneath it (dermis) results in the development of blisters after an injury.
The classification is determined by the location where blisters form: epidermolytic or EB simplex (EBS), junctional EB (JEB), and dermolytic or dystrophic EB (DEB). Each of them contains multiple unique categories. Junctional Epidermolysis Bullosa (JEB) is characterized by the development of blisters in the basement membrane caused by genetic abnormalities in the collagen XVII and laminin genes. This characteristic is inherited in an autosomal recessive manner and encompasses multiple clinical manifestations.
The survival rate for infants with Herlitz EB is frequently low, with a mortality rate of 40% within the first year of life. Additional observations encompass any symptoms arising from widespread blistering of the epithelial tissue, affecting the respiratory, gastrointestinal, and genitourinary systems.
Non-Herlitz mitis subtype These children may experience moderate or severe illness at birth yet manage to survive infancy and show clinical improvement as they grow older. Non-Herlitz generalized atrophic benign epidermolysis bullosa (EB) manifests at birth and individuals affected by this condition live into maturity. They experience ongoing blistering following injury, which is especially noticeable in higher temperatures, and the lesions heal with atrophy. The individual may experience nail dystrophy, which refers to abnormal nail growth, as well as either nonscarring or scarring alopecia, which is hair loss that may or may not leave permanent scars. There may also be mild involvement of the oral mucous membranes, which are the moist tissues inside the mouth. Additionally, enamel defects, which are abnormalities in the outer layer of teeth, may develop.
Herlitz EB is a medical condition. The individual presents with either widespread blistering at birth or specific and severe inflammation around the mouth, accompanied by nail loss and affected mucous membranes. The skin may be entirely stripped, resulting in the painful discharge of an eroded area. Non-Herlitz mitis subtype During childhood, there are occurrences of nonhealing erosions around the mouth and other facial areas, known as periorificial. Non-Herlitz generalized atrophic benign EB is characterized by widespread blistering and erosions on the limbs, trunk, face, and scalp.
The diagnosis relies on the clinical presentation and medical history. Histopathology assesses the degree of separation, which is further characterized by electron microscopy and/or immunohistochemistry mapping.
Management encompasses the provision of supportive skin care, supportive care for various organ systems, and systemic therapies for problems. Wound treatment, dietary assistance, and infection control are essential. Patients with more serious conditions receive treatment similar to that provided in a burn unit. The process begins with a gentle bathing and cleansing, which is then followed by the application of protective emollients and nonadherent dressings.
Hereditary epidermolysis bullosa refers to a range of uncommon genetic skin disorders. Disruption of the structural integrity of the outermost layer of skin (epidermis) and/or the layer beneath it (dermis) results in the development of blisters after an injury.
The classification is determined by the location where blisters form: epidermolytic or EB simplex (EBS), junctional EB (JEB), and dermolytic or dystrophic EB (DEB). Each of them contains multiple unique categories. Junctional Epidermolysis Bullosa (JEB) is characterized by the development of blisters in the basement membrane caused by genetic abnormalities in the collagen XVII and laminin genes. This characteristic is inherited in an autosomal recessive manner and encompasses multiple clinical manifestations.
The survival rate for infants with Herlitz EB is frequently low, with a mortality rate of 40% within the first year of life. Additional observations encompass any symptoms arising from widespread blistering of the epithelial tissue, affecting the respiratory, gastrointestinal, and genitourinary systems.
Non-Herlitz mitis subtype These children may experience moderate or severe illness at birth yet manage to survive infancy and show clinical improvement as they grow older. Non-Herlitz generalized atrophic benign epidermolysis bullosa (EB) manifests at birth and individuals affected by this condition live into maturity. They experience ongoing blistering following injury, which is especially noticeable in higher temperatures, and the lesions heal with atrophy. The individual may experience nail dystrophy, which refers to abnormal nail growth, as well as either nonscarring or scarring alopecia, which is hair loss that may or may not leave permanent scars. There may also be mild involvement of the oral mucous membranes, which are the moist tissues inside the mouth. Additionally, enamel defects, which are abnormalities in the outer layer of teeth, may develop.
Herlitz EB is a medical condition. The individual presents with either widespread blistering at birth or specific and severe inflammation around the mouth, accompanied by nail loss and affected mucous membranes. The skin may be entirely stripped, resulting in the painful discharge of an eroded area. Non-Herlitz mitis subtype During childhood, there are occurrences of nonhealing erosions around the mouth and other facial areas, known as periorificial. Non-Herlitz generalized atrophic benign EB is characterized by widespread blistering and erosions on the limbs, trunk, face, and scalp.
The diagnosis relies on the clinical presentation and medical history. Histopathology assesses the degree of separation, which is further characterized by electron microscopy and/or immunohistochemistry mapping.
Management encompasses the provision of supportive skin care, supportive care for various organ systems, and systemic therapies for problems. Wound treatment, dietary assistance, and infection control are essential. Patients with more serious conditions receive treatment similar to that provided in a burn unit. The process begins with a gentle bathing and cleansing, which is then followed by the application of protective emollients and nonadherent dressings.
- Published on
Dermatology - Oropharyngeal Manifestations of Lupus Erythematosus.
About 25% of individuals with persistent cutaneous lupus erythematosus get mucosal involvement. Lupus erythematosus is a severe autoimmune disease that affects multiple systems in the body, specifically targeting connective tissue and blood vessels. Prevalence of this condition is ninefold higher in women compared to men, and it is more prevalent among individuals of African heritage. The onset typically occurs in the third or fourth decade of life, and risk factors for this condition include a family history of the disease and exposure to ultraviolet (UV) radiation.
Arthralgia or arthritis, abdominal pain, and CNS symptoms are accompanied by fatigue, fever, weight loss, and malaise.
Ulcers develop in purpuric necrotic lesions of the palate (80%), buccal mucosa, or gums in cases of acute systemic lupus erythematosus. Oropharyngeal lesions in chronic lupus are found in several locations, including the buccal mucosa, palate, alveolar process, tongue, and vermilian border of the lips. The lesions initially appear as painless red spots that gradually develop into long-lasting plaques. These plaques have well defined edges with irregularly shaped white borders, accompanied by white streaks and visible dilated blood vessels.
Central depression and painful ulceration manifest in more mature lesions. The skin lesions persist for a duration ranging from weeks (acute) to months (chronic) and are accompanied by itching or a burning sensation. Chronic lupus skin lesions manifest as vivid red bumps that develop into well-defined, circular or oval-shaped, ring-like or multi-cyclic patches with uneven edges and stubborn scales that are challenging to eliminate. Plaques undergo peripheral expansion and central regression, leading to atrophy and scarring. "Burned out" lesions might appear as pink or white macules and scars, but they can also be hyperpigmented.
The diagnosis is established by evaluating clinical symptoms, histology, lupus band test, and serology according to the revised criteria set by the American Rheumatism Association (ARA).
Recommendation: Encourage the individual to relax and avoid exposure to ultraviolet (UV) radiation. Administer prednisone at a dosage of 60 mg per day, divided into many doses. Additionally, consider using immunosuppressants if there is involvement of the central nervous system or kidneys, hemolytic crises, thrombocytopenia, or severe sickness. Hydroxychloroquine is effective in treating skin lesions during the subacute and chronic periods, but it does not decrease the requirement for prednisone. Adhere to safety measures when use hydroxychloroquine. Other options encompass chloroquine or quinacrine.
About 25% of individuals with persistent cutaneous lupus erythematosus get mucosal involvement. Lupus erythematosus is a severe autoimmune disease that affects multiple systems in the body, specifically targeting connective tissue and blood vessels. Prevalence of this condition is ninefold higher in women compared to men, and it is more prevalent among individuals of African heritage. The onset typically occurs in the third or fourth decade of life, and risk factors for this condition include a family history of the disease and exposure to ultraviolet (UV) radiation.
Arthralgia or arthritis, abdominal pain, and CNS symptoms are accompanied by fatigue, fever, weight loss, and malaise.
Ulcers develop in purpuric necrotic lesions of the palate (80%), buccal mucosa, or gums in cases of acute systemic lupus erythematosus. Oropharyngeal lesions in chronic lupus are found in several locations, including the buccal mucosa, palate, alveolar process, tongue, and vermilian border of the lips. The lesions initially appear as painless red spots that gradually develop into long-lasting plaques. These plaques have well defined edges with irregularly shaped white borders, accompanied by white streaks and visible dilated blood vessels.
Central depression and painful ulceration manifest in more mature lesions. The skin lesions persist for a duration ranging from weeks (acute) to months (chronic) and are accompanied by itching or a burning sensation. Chronic lupus skin lesions manifest as vivid red bumps that develop into well-defined, circular or oval-shaped, ring-like or multi-cyclic patches with uneven edges and stubborn scales that are challenging to eliminate. Plaques undergo peripheral expansion and central regression, leading to atrophy and scarring. "Burned out" lesions might appear as pink or white macules and scars, but they can also be hyperpigmented.
The diagnosis is established by evaluating clinical symptoms, histology, lupus band test, and serology according to the revised criteria set by the American Rheumatism Association (ARA).
Recommendation: Encourage the individual to relax and avoid exposure to ultraviolet (UV) radiation. Administer prednisone at a dosage of 60 mg per day, divided into many doses. Additionally, consider using immunosuppressants if there is involvement of the central nervous system or kidneys, hemolytic crises, thrombocytopenia, or severe sickness. Hydroxychloroquine is effective in treating skin lesions during the subacute and chronic periods, but it does not decrease the requirement for prednisone. Adhere to safety measures when use hydroxychloroquine. Other options encompass chloroquine or quinacrine.
- Published on
Dermatology - Cellulitis
Cellulitis is a rapid and expanding infection that affects the skin and underlying tissues. The point of entry is typically evident, and Staphylococcus aureus is the predominant pathogen.
Erysipelas is a form of cellulitis that affects the lymphatic system of the skin. It is typically caused by beta-hemolytic streptococci bacteria. prevalent pathogens in chronic soft tissue infections include Nocardia spp, Sporothrix schenckii, Madurella spp, Scedosporium spp, and nontuberculous mycobacteria. In cases of dog or cat bites, prevalent pathogens are Pasteurella spp and Capnocytophaga canimorsus.
Risk factors encompass host defense deficiencies, diabetes mellitus, substance and alcohol misuse, malignancy and cancer treatment, persistent lymphedema, and prior occurrences of cellulitis/erysipelas.
The onset of fever and chills may occur swiftly, preceding the clinical manifestation of cellulitis. Elevated body temperature (38.5°C) and shivering commonly linked to group A streptococcal infection. Lymph nodes might exhibit regional enlargement and tenderness.
A crimson, scorching, swollen, lustrous patch that starts at the point of entry expands with movement towards the center and has clearly defined edges that are uneven and somewhat raised. Plaque can lead to the formation of vesicles, bullae, erosions, abscesses, bleeding, and necrosis. The lesions exhibit tenderness and cause pain.
The diagnosis is mostly made through clinical assessment of the appearance of the lesion and the patient's medical history. Confirmation through culture is performed when necessary. To confirm the presence of necrotizing fasciitis, it is recommended to do a deep biopsy and frozen section histology. The differential diagnosis comprises deep vein thrombophlebitis, early contact dermatitis, urticaria, insect bite, fixed drug eruption, erythema nodosum, acute gout, and erythema migrans. If necrosis is observed, it is advisable to investigate the possibility of vascular disease, calciphylaxis, warfarin-induced necrosis, traumatic damage, cryoglobulinemia, fixed drug eruption, pyoderma gangrenosum, and brown recluse spider bite.
Cellulitis should be treated with high-dose antibiotics based on the specific type of bacteria that is suspected or proven through culture, taking into consideration its sensitivity.
Cellulitis is a rapid and expanding infection that affects the skin and underlying tissues. The point of entry is typically evident, and Staphylococcus aureus is the predominant pathogen.
Erysipelas is a form of cellulitis that affects the lymphatic system of the skin. It is typically caused by beta-hemolytic streptococci bacteria. prevalent pathogens in chronic soft tissue infections include Nocardia spp, Sporothrix schenckii, Madurella spp, Scedosporium spp, and nontuberculous mycobacteria. In cases of dog or cat bites, prevalent pathogens are Pasteurella spp and Capnocytophaga canimorsus.
Risk factors encompass host defense deficiencies, diabetes mellitus, substance and alcohol misuse, malignancy and cancer treatment, persistent lymphedema, and prior occurrences of cellulitis/erysipelas.
The onset of fever and chills may occur swiftly, preceding the clinical manifestation of cellulitis. Elevated body temperature (38.5°C) and shivering commonly linked to group A streptococcal infection. Lymph nodes might exhibit regional enlargement and tenderness.
A crimson, scorching, swollen, lustrous patch that starts at the point of entry expands with movement towards the center and has clearly defined edges that are uneven and somewhat raised. Plaque can lead to the formation of vesicles, bullae, erosions, abscesses, bleeding, and necrosis. The lesions exhibit tenderness and cause pain.
The diagnosis is mostly made through clinical assessment of the appearance of the lesion and the patient's medical history. Confirmation through culture is performed when necessary. To confirm the presence of necrotizing fasciitis, it is recommended to do a deep biopsy and frozen section histology. The differential diagnosis comprises deep vein thrombophlebitis, early contact dermatitis, urticaria, insect bite, fixed drug eruption, erythema nodosum, acute gout, and erythema migrans. If necrosis is observed, it is advisable to investigate the possibility of vascular disease, calciphylaxis, warfarin-induced necrosis, traumatic damage, cryoglobulinemia, fixed drug eruption, pyoderma gangrenosum, and brown recluse spider bite.
Cellulitis should be treated with high-dose antibiotics based on the specific type of bacteria that is suspected or proven through culture, taking into consideration its sensitivity.
- Published on
Dermatology - Thrombocytopenic Purpura
Thrombocytopenic purpura is a condition where there is a decrease in the number of platelets in the blood, leading to the development of skin hemorrhages. These hemorrhages can occur either at sites of minor trauma or pressure when the platelet count is below 40,000/μL, or they can happen spontaneously when the platelet count is below 10,000/μL. The low platelet count in thrombocytopenic purpura can be caused by reduced platelet production, splenic sequestration, or increased platelet destruction.
Petechiae are tiny red spots that do not fade when pressed and cannot be felt. Over time, they change color from red to brown and may develop a yellowish-green hue. Ecchymoses are discolorations characterized by the presence of black-and-blue dots, which indicate a more extensive occurrence of bleeding. Vibices are elongated areas of bleeding that occur as a result of physical injury or pressure. Lesions are typically found on the legs and upper trunk, however they can occur in any location.
Petachiae may be observed on the palate, accompanied by gingival hemorrhage.
The diagnosis is established through clinical examination and subsequently confirmed by laboratory tests and platelet count assessment. Exclude HIV infection (using ELISA test) and vasculitis (via biopsy). The differential diagnosis comprises senile purpura, scurvy, progressive pigmentary purpura (Schamberg disease), purpura resulting from severe Valsalva maneuver (coughing, vomiting/retching), traumatic purpura, factitious or iatrogenic purpura, and vasculitis.
Determine the root cause of thrombocytopenia and rectify it, if feasible. Oral glucocorticoids, high-dose intravenous immunoglobulins, platelet transfusion, or splenectomy may be necessary.
Thrombocytopenic purpura is a condition where there is a decrease in the number of platelets in the blood, leading to the development of skin hemorrhages. These hemorrhages can occur either at sites of minor trauma or pressure when the platelet count is below 40,000/μL, or they can happen spontaneously when the platelet count is below 10,000/μL. The low platelet count in thrombocytopenic purpura can be caused by reduced platelet production, splenic sequestration, or increased platelet destruction.
Petechiae are tiny red spots that do not fade when pressed and cannot be felt. Over time, they change color from red to brown and may develop a yellowish-green hue. Ecchymoses are discolorations characterized by the presence of black-and-blue dots, which indicate a more extensive occurrence of bleeding. Vibices are elongated areas of bleeding that occur as a result of physical injury or pressure. Lesions are typically found on the legs and upper trunk, however they can occur in any location.
Petachiae may be observed on the palate, accompanied by gingival hemorrhage.
The diagnosis is established through clinical examination and subsequently confirmed by laboratory tests and platelet count assessment. Exclude HIV infection (using ELISA test) and vasculitis (via biopsy). The differential diagnosis comprises senile purpura, scurvy, progressive pigmentary purpura (Schamberg disease), purpura resulting from severe Valsalva maneuver (coughing, vomiting/retching), traumatic purpura, factitious or iatrogenic purpura, and vasculitis.
Determine the root cause of thrombocytopenia and rectify it, if feasible. Oral glucocorticoids, high-dose intravenous immunoglobulins, platelet transfusion, or splenectomy may be necessary.
- Published on
Dermatology - Chickenpox
Varicella zoster virus (VZV), sometimes known as chickenpox, infection
VZV is a human herpes virus that is spread through the air by tiny droplets and through direct contact between people.
It is typically indicative and predominantly manifests throughout childhood. Following the initial infection, VZV forms a persistent infection in sensory ganglia, leading to lifelong infection. Recurrences of the illness, known as herpes zoster, occur when the immune response weakens. The VZV vaccine has significantly decreased the occurrence of both varicella and herpes zoster.
The initial skin abnormalities appear on the face and head, then extend downwards to the trunk and limbs. They are most abundant in regions that are least subjected to pressure, such as the areas between the shoulder blades, flanks, armpits, and the bends of the knees and elbows. The palms and soles are typically unaffected. Children may experience central nervous system (CNS) involvement, including cerebellar ataxia, encephalitis, and Reye syndrome.
Respiratory problems are frequently experienced by adolescents and adults.
Abnormalities
The primary skin abnormalities are small raised bumps (often not visible) that may manifest as swollen, itchy areas and rapidly progress to fluid-filled blisters, which are shallow and delicate, accompanied by redness in the surrounding area. The vesicles undergo rapid transformation into pustules and crusted erosions within a span of 8 to 12 hours. During following crop cycles, it is possible to observe all stages of evolution simultaneously, namely papules, vesicles, pustules, and crusts, which collectively exhibit polymorphism. Crusted erosions often undergo healing within a period of 1 to 3 weeks, resulting in the formation of a pink, somewhat sunken base. Distinctive indentations that are caused by punching and are long-lasting may remain. One may see oropharyngeal vesicles and subsequent erosions, especially on the palate.
The diagnosis is determined through clinical examination and validated by conducting specific tests such as direct fluorescent antibody (DFA) test, Tzanck smear, serology, or dermatopathology, as required. The differential diagnosis comprises disseminated herpes simplex virus (HSV) infection, cutaneous dissemination of zoster, eczema herpeticum, rickettsia pox, and enterovirus infections.
Manage pruritus by using antihistamines and lotions. Refrain from using antipyretics as they have a risk of causing Reye syndrome.
To reduce the severity of the illness, antiviral drugs should be administered within 24 hours of the symptoms appearing. For infants, valaciclovir should be given at a dose of 20 mg/kg every 8 hours for five days, or acyclovir at a dose of 20 mg/kg every 6 hours for 5 days. Adolescents and adults should take valaciclovir at a dose of 1 g every 8 hours for 7 days. For those with weakened immune systems, the recommended dosage is 1 gram of valaciclovir every 8 hours for a duration of 7 to 10 days. Alternatively, acyclovir can be taken at a dosage of 800 milligrams five times a day, or famciclovir can be taken at a dosage of 500 milligrams every 8 hours for the same duration. Administer intravenous acyclovir or foscarnet to those with severe immunocompromise.
Varicella zoster virus (VZV), sometimes known as chickenpox, infection
VZV is a human herpes virus that is spread through the air by tiny droplets and through direct contact between people.
It is typically indicative and predominantly manifests throughout childhood. Following the initial infection, VZV forms a persistent infection in sensory ganglia, leading to lifelong infection. Recurrences of the illness, known as herpes zoster, occur when the immune response weakens. The VZV vaccine has significantly decreased the occurrence of both varicella and herpes zoster.
The initial skin abnormalities appear on the face and head, then extend downwards to the trunk and limbs. They are most abundant in regions that are least subjected to pressure, such as the areas between the shoulder blades, flanks, armpits, and the bends of the knees and elbows. The palms and soles are typically unaffected. Children may experience central nervous system (CNS) involvement, including cerebellar ataxia, encephalitis, and Reye syndrome.
Respiratory problems are frequently experienced by adolescents and adults.
Abnormalities
The primary skin abnormalities are small raised bumps (often not visible) that may manifest as swollen, itchy areas and rapidly progress to fluid-filled blisters, which are shallow and delicate, accompanied by redness in the surrounding area. The vesicles undergo rapid transformation into pustules and crusted erosions within a span of 8 to 12 hours. During following crop cycles, it is possible to observe all stages of evolution simultaneously, namely papules, vesicles, pustules, and crusts, which collectively exhibit polymorphism. Crusted erosions often undergo healing within a period of 1 to 3 weeks, resulting in the formation of a pink, somewhat sunken base. Distinctive indentations that are caused by punching and are long-lasting may remain. One may see oropharyngeal vesicles and subsequent erosions, especially on the palate.
The diagnosis is determined through clinical examination and validated by conducting specific tests such as direct fluorescent antibody (DFA) test, Tzanck smear, serology, or dermatopathology, as required. The differential diagnosis comprises disseminated herpes simplex virus (HSV) infection, cutaneous dissemination of zoster, eczema herpeticum, rickettsia pox, and enterovirus infections.
Manage pruritus by using antihistamines and lotions. Refrain from using antipyretics as they have a risk of causing Reye syndrome.
To reduce the severity of the illness, antiviral drugs should be administered within 24 hours of the symptoms appearing. For infants, valaciclovir should be given at a dose of 20 mg/kg every 8 hours for five days, or acyclovir at a dose of 20 mg/kg every 6 hours for 5 days. Adolescents and adults should take valaciclovir at a dose of 1 g every 8 hours for 7 days. For those with weakened immune systems, the recommended dosage is 1 gram of valaciclovir every 8 hours for a duration of 7 to 10 days. Alternatively, acyclovir can be taken at a dosage of 800 milligrams five times a day, or famciclovir can be taken at a dosage of 500 milligrams every 8 hours for the same duration. Administer intravenous acyclovir or foscarnet to those with severe immunocompromise.
- Published on
Dermatology - Diabetic Neuropathy
The condition known as peripheral neuropathy is the underlying cause of the condition commonly referred to as the "diabetic foot." Additional variables include angiopathy, atherosclerosis, and infection, which are frequently observed in combination. Diabetic neuropathy is a condition that affects both the motor and sensory functions. Motor neuropathy specifically causes weakness and muscle deterioration in the extremities.
The onset of sensory loss initiates in the toes and gradually advances throughout the legs. Sensations of tingling, burning, and intense aching may also be evident.
Abnormalities
The patient's sensory neuropathy increases their susceptibility to developing neurotropic ulcers on bony prominences of the feet, typically on the great toe and sole as depicted. The ulcers are encircled by a band of thickened skin and can spread to the underlying joint and bone, resulting in osteomyelitis.
Nerve conduction examinations typically demonstrate decreased amplitudes and considerable slowing of conduction velocities. Nerve biopsy indicates degeneration of the axons, increased growth of endothelial cells, and sometimes inflammation around blood vessels.
Strict regulation of glucose levels might decrease the likelihood of developing neuropathy or enhance the existing neuropathy. All infections should be managed with suitable antibiotic agents.
The management of pain can involve the use of antiepileptics, antidepressants, sodium channel blockers, and other analgesics. Ulcers should undergo debridement, followed by the application of moist wound treatment, protective dressings, and off-loading, typically involving nonweight bearing.
The condition known as peripheral neuropathy is the underlying cause of the condition commonly referred to as the "diabetic foot." Additional variables include angiopathy, atherosclerosis, and infection, which are frequently observed in combination. Diabetic neuropathy is a condition that affects both the motor and sensory functions. Motor neuropathy specifically causes weakness and muscle deterioration in the extremities.
The onset of sensory loss initiates in the toes and gradually advances throughout the legs. Sensations of tingling, burning, and intense aching may also be evident.
Abnormalities
The patient's sensory neuropathy increases their susceptibility to developing neurotropic ulcers on bony prominences of the feet, typically on the great toe and sole as depicted. The ulcers are encircled by a band of thickened skin and can spread to the underlying joint and bone, resulting in osteomyelitis.
Nerve conduction examinations typically demonstrate decreased amplitudes and considerable slowing of conduction velocities. Nerve biopsy indicates degeneration of the axons, increased growth of endothelial cells, and sometimes inflammation around blood vessels.
Strict regulation of glucose levels might decrease the likelihood of developing neuropathy or enhance the existing neuropathy. All infections should be managed with suitable antibiotic agents.
The management of pain can involve the use of antiepileptics, antidepressants, sodium channel blockers, and other analgesics. Ulcers should undergo debridement, followed by the application of moist wound treatment, protective dressings, and off-loading, typically involving nonweight bearing.
- Published on
Dermatology - Gout
Gout is a form of arthritis that is characterized by severe pain, redness, and tenderness in the joints, most commonly affecting the big
Gout is a medical condition characterized by the accumulation of monosodium urate crystals in the synovial fluid and joints. Gout can manifest both with and without hyperuricemia, renal dysfunction, and nephrolithiasis.
Acute gouty arthritis typically manifests in individuals of middle age. Gout often impacts a solitary joint in the lower extremities, commonly the first metatarsophalangeal joint, and may sometimes affect the fingers. Over time, the assaults tend to extend to several joints. Intercritical gout refers to the period of time that occurs between episodes of gout. In cases of chronic tophaceous gout, individuals seldom experience periods without symptoms.
Precise diagnosis relies on the identification of needle-shaped crystals that exhibit birefringence within cells, using polarized microscopy. The histopathologic analysis of a gouty tophus shows the presence of granulomatous inflammation surrounding yellow-brown urate crystals or needle-like spaces arranged in a radial pattern. These spaces indicate the dissolution of crystals throughout the examination process.
Elevated uric acid levels may be detected through laboratory analysis, although it is not essential for diagnosis.
Acute arthritic episodes frequently result in leukocytosis and an increased sedimentation rate.
The objective of therapy for acute attacks is to achieve analgesia and decrease inflammation using nonsteroidal anti-inflammatory medications, colchicine, and corticosteroids. Indomethacin and colchicine have both demonstrated pain-reducing benefits in randomized controlled studies. Colchicine, when administered as 1.2 mg followed by 0.6 mg after 1 hour, has been found to minimize medication interactions and gastrointestinal adverse effects.
Corticosteroids are also considered to be efficacious. Given the frequent presence of several comorbidities in patients, it is imperative to tailor therapy to each individual. Administer medication for a duration of 7 to 10 days following the acute episode, and consider continuing preventive therapy for a period of 3 to 6 months. For individuals who have experienced a single incident, conservative therapy involves avoiding medications that reduce the excretion of uric acid, such as thiazide or loop diuretics, aspirin, pyrazinamide, or niacin. It also includes maintaining proper hydration, achieving weight loss, managing hypertension or hyperlipidemia, and reducing the intake of purine. Uric acid-lowering therapy is recommended for patients with chronic tophaceous gout, renal calculi, significantly elevated serum uric acid levels, high serum uric acid levels in the presence of a known family history of gout (such as a known deficiency of relevant enzymes), or patients undergoing acute chemotherapy. Uricosurics such as probenecid, sulfinpyrazone, and benzbromarone, as well as xanthine oxidase inhibitors like allopurinol and febuxostat, are employed to keep the blood urate level below 6 mg/dL.
Gout is a form of arthritis that is characterized by severe pain, redness, and tenderness in the joints, most commonly affecting the big
Gout is a medical condition characterized by the accumulation of monosodium urate crystals in the synovial fluid and joints. Gout can manifest both with and without hyperuricemia, renal dysfunction, and nephrolithiasis.
Acute gouty arthritis typically manifests in individuals of middle age. Gout often impacts a solitary joint in the lower extremities, commonly the first metatarsophalangeal joint, and may sometimes affect the fingers. Over time, the assaults tend to extend to several joints. Intercritical gout refers to the period of time that occurs between episodes of gout. In cases of chronic tophaceous gout, individuals seldom experience periods without symptoms.
Precise diagnosis relies on the identification of needle-shaped crystals that exhibit birefringence within cells, using polarized microscopy. The histopathologic analysis of a gouty tophus shows the presence of granulomatous inflammation surrounding yellow-brown urate crystals or needle-like spaces arranged in a radial pattern. These spaces indicate the dissolution of crystals throughout the examination process.
Elevated uric acid levels may be detected through laboratory analysis, although it is not essential for diagnosis.
Acute arthritic episodes frequently result in leukocytosis and an increased sedimentation rate.
The objective of therapy for acute attacks is to achieve analgesia and decrease inflammation using nonsteroidal anti-inflammatory medications, colchicine, and corticosteroids. Indomethacin and colchicine have both demonstrated pain-reducing benefits in randomized controlled studies. Colchicine, when administered as 1.2 mg followed by 0.6 mg after 1 hour, has been found to minimize medication interactions and gastrointestinal adverse effects.
Corticosteroids are also considered to be efficacious. Given the frequent presence of several comorbidities in patients, it is imperative to tailor therapy to each individual. Administer medication for a duration of 7 to 10 days following the acute episode, and consider continuing preventive therapy for a period of 3 to 6 months. For individuals who have experienced a single incident, conservative therapy involves avoiding medications that reduce the excretion of uric acid, such as thiazide or loop diuretics, aspirin, pyrazinamide, or niacin. It also includes maintaining proper hydration, achieving weight loss, managing hypertension or hyperlipidemia, and reducing the intake of purine. Uric acid-lowering therapy is recommended for patients with chronic tophaceous gout, renal calculi, significantly elevated serum uric acid levels, high serum uric acid levels in the presence of a known family history of gout (such as a known deficiency of relevant enzymes), or patients undergoing acute chemotherapy. Uricosurics such as probenecid, sulfinpyrazone, and benzbromarone, as well as xanthine oxidase inhibitors like allopurinol and febuxostat, are employed to keep the blood urate level below 6 mg/dL.
- Published on
Dermatology - Systemic lupus erythematosus (SLE)
Systemic lupus erythematosus is a severe autoimmune illness that affects multiple systems in the body, including the connective tissue and blood vessels. The prevalence of this condition is ninefold higher in women compared to men, and it is more prevalent among individuals of African heritage. The onset often occurs in the third or fourth decade of life, and triggering factors include a family history of the condition and exposure to ultraviolet (UV) radiation.
Arthralgia or arthritis, abdominal pain, and CNS symptoms are accompanied by fatigue, fever, weight loss, and malaise.
Abnormalities
The lesions last for a duration ranging from weeks (acute) to months (chronic) and are characterized by itchiness or a burning sensation. During the subacute and acute stages of the disease, a rash resembling a butterfly shape appears on the cheeks of the face. This rash is red, continuous, and clearly defined, with thin layers of skin peeling off, occasional open sores, and dried secretions. During the subacute phase, there are well-defined psoriasiform papulosquamous lesions in areas exposed to light. These lesions have a slight delicate scaling and develop into bright red confluent plaques that are oval, arciform, or polycyclic, similar to those seen in psoriasis. Additionally, there are annular, bright red lesions with central regression and minimal scaling. Both conditions may exhibit telangiectasia, although there is an absence of follicular clogging and minimal induration. The lesions disappear with little tissue shrinkage (without scarring) and reduced pigmentation. During the chronic phase, the lesions first appear as brilliant red papules that gradually develop into strongly defined plaques. These plaques are covered with scales that are firmly attached and have spines on the undersurface, like carpet tacks when observed under a magnifying lens. Plaques exhibit a circular or oval shape, and can be annular or polycyclic, with uneven edges. They grow outward from the edges and shrink inward from the center, leading to tissue atrophy and scarring. Lesions that have been "burned out" can appear as pink or white macules and scars. However, they may also be hyperpigmented, particularly in individuals with brown or black skin.
Medical assessment and determination of a person's health condition.
The diagnosis is established by evaluating clinical symptoms, histology, lupus band test, and serology according to the revised criteria set by the American Rheumatism Association (ARA).
Standard precautions include relaxation and refraining from direct sunlight exposure. Administer prednisone at a dosage of 60 mg per day, divided into multiple doses. Additionally, consider using immunosuppressants if there are indications of central nervous system or renal involvement, hemolytic crises, thrombocytopenia, or severe sickness. Hydroxychloroquine is effective in treating skin lesions in subacute and chronic systemic lupus erythematosus (SLE), but it does not decrease the requirement for prednisone.
Adhere to safety measures when using hydroxychloroquine. Other options encompass chloroquine or quinacrine.
Systemic lupus erythematosus is a severe autoimmune illness that affects multiple systems in the body, including the connective tissue and blood vessels. The prevalence of this condition is ninefold higher in women compared to men, and it is more prevalent among individuals of African heritage. The onset often occurs in the third or fourth decade of life, and triggering factors include a family history of the condition and exposure to ultraviolet (UV) radiation.
Arthralgia or arthritis, abdominal pain, and CNS symptoms are accompanied by fatigue, fever, weight loss, and malaise.
Abnormalities
The lesions last for a duration ranging from weeks (acute) to months (chronic) and are characterized by itchiness or a burning sensation. During the subacute and acute stages of the disease, a rash resembling a butterfly shape appears on the cheeks of the face. This rash is red, continuous, and clearly defined, with thin layers of skin peeling off, occasional open sores, and dried secretions. During the subacute phase, there are well-defined psoriasiform papulosquamous lesions in areas exposed to light. These lesions have a slight delicate scaling and develop into bright red confluent plaques that are oval, arciform, or polycyclic, similar to those seen in psoriasis. Additionally, there are annular, bright red lesions with central regression and minimal scaling. Both conditions may exhibit telangiectasia, although there is an absence of follicular clogging and minimal induration. The lesions disappear with little tissue shrinkage (without scarring) and reduced pigmentation. During the chronic phase, the lesions first appear as brilliant red papules that gradually develop into strongly defined plaques. These plaques are covered with scales that are firmly attached and have spines on the undersurface, like carpet tacks when observed under a magnifying lens. Plaques exhibit a circular or oval shape, and can be annular or polycyclic, with uneven edges. They grow outward from the edges and shrink inward from the center, leading to tissue atrophy and scarring. Lesions that have been "burned out" can appear as pink or white macules and scars. However, they may also be hyperpigmented, particularly in individuals with brown or black skin.
Medical assessment and determination of a person's health condition.
The diagnosis is established by evaluating clinical symptoms, histology, lupus band test, and serology according to the revised criteria set by the American Rheumatism Association (ARA).
Standard precautions include relaxation and refraining from direct sunlight exposure. Administer prednisone at a dosage of 60 mg per day, divided into multiple doses. Additionally, consider using immunosuppressants if there are indications of central nervous system or renal involvement, hemolytic crises, thrombocytopenia, or severe sickness. Hydroxychloroquine is effective in treating skin lesions in subacute and chronic systemic lupus erythematosus (SLE), but it does not decrease the requirement for prednisone.
Adhere to safety measures when using hydroxychloroquine. Other options encompass chloroquine or quinacrine.
- Published on
Dermatology - Polyarteritis Nodosa
Renal and visceral arteries are also affected by polyarteritis nodosa, a multisystem necrotizing vasculitis affecting the small and medium-sized muscle arteries. A rare variation of polyarteritis nodosa, cutaneous polyarteritis, is characterized by a skin- and occasionally peripheral nerve-limited vasculitis. About thirty percent of cases had hepatitis B involved.
Small- and medium-sized muscle arteries may develop necrotizing inflammation, which can then expand circumferentially to affect nearby veins. Patients exhibit painful skin lesions, fever, myalgia, and asthma. In addition to hypertension, the patients may experience mixed motor/sensory involvement with mononeuritis multiplex pattern, congestive heart failure, pericarditis, conduction system defects, myocardial infarction, cerebrovascular accident, nausea, vomiting, abdominal pain, ocular vasculitis, retinal artery aneurysm, optic disc edema, and renal failure.
Damage
Segmental lesions typically include bifurcations. Subcutaneous inflammatory nodules, measuring 0.5–2 cm, are bright red to bluish and run parallel to the affected artery. Livedo reticularis is present along with violaceous lesions that develop confluent to generate painful subcutaneous plaques. A cluster of nodular lesions is identified by a pathognomonic "starburst" livedo. Ischemia of nodules is followed by ulcers. Lesions typically affect both lower legs and thighs, but they can also occur in the arms, torso, head, neck, and buttocks. Days to months pass after the lesions disappear, leaving behind postinflammatory or violaceous hyperpigmentation.
The diagnosis is made clinically and verified by biopsy, which reveals polymorphonuclear neutrophils in the perivascular and muscular vessel wall layers as well as fibrinoid necrosis of the vessel wall with compromised lumen, thrombosis, and infarction of the tissues supplied by the involved vessel, either with or without hemorrhage.
Oral glucocorticoids are used as treatment: 1 mg/kg body weight of prednisone and 2 mg/kg of cyclophosphamide daily.
Renal and visceral arteries are also affected by polyarteritis nodosa, a multisystem necrotizing vasculitis affecting the small and medium-sized muscle arteries. A rare variation of polyarteritis nodosa, cutaneous polyarteritis, is characterized by a skin- and occasionally peripheral nerve-limited vasculitis. About thirty percent of cases had hepatitis B involved.
Small- and medium-sized muscle arteries may develop necrotizing inflammation, which can then expand circumferentially to affect nearby veins. Patients exhibit painful skin lesions, fever, myalgia, and asthma. In addition to hypertension, the patients may experience mixed motor/sensory involvement with mononeuritis multiplex pattern, congestive heart failure, pericarditis, conduction system defects, myocardial infarction, cerebrovascular accident, nausea, vomiting, abdominal pain, ocular vasculitis, retinal artery aneurysm, optic disc edema, and renal failure.
Damage
Segmental lesions typically include bifurcations. Subcutaneous inflammatory nodules, measuring 0.5–2 cm, are bright red to bluish and run parallel to the affected artery. Livedo reticularis is present along with violaceous lesions that develop confluent to generate painful subcutaneous plaques. A cluster of nodular lesions is identified by a pathognomonic "starburst" livedo. Ischemia of nodules is followed by ulcers. Lesions typically affect both lower legs and thighs, but they can also occur in the arms, torso, head, neck, and buttocks. Days to months pass after the lesions disappear, leaving behind postinflammatory or violaceous hyperpigmentation.
The diagnosis is made clinically and verified by biopsy, which reveals polymorphonuclear neutrophils in the perivascular and muscular vessel wall layers as well as fibrinoid necrosis of the vessel wall with compromised lumen, thrombosis, and infarction of the tissues supplied by the involved vessel, either with or without hemorrhage.
Oral glucocorticoids are used as treatment: 1 mg/kg body weight of prednisone and 2 mg/kg of cyclophosphamide daily.
- Published on
Dermatology - Graft Versus Host Disease
The entirety of organ failure brought on by histoincompatible, immunocompetent donor cells attacking immunocompetent host tissues is known as graft-versus-host disease (GVHD). A particular organ's expression of GVHD is known as graft-versus-host reaction (GVHR) (e.g., cutaneous GVHR). Usually happening 10–30 days following bone marrow transplantation (BMT), acute cutaneous GVHR ensues. It is the most common and earliest. After liver and other gastrointestinal transplants, GVHR are also frequently observed. Chronic cutaneous GVHR presents as lichenoid and sclerodermoid alterations and happens more than 60 days following allogeneic BMT.
Localized or widespread pruritus, discomfort upon pressure, nausea, vomiting, stomach pain, watery diarrhea, and jaundice are some of the symptoms of acute GVHR.
First, the hands, feet, and upper trunk all develop small, distinct macules and/or papules, particularly on the palms and soles. On the face, macules confluence and are frequently painful and erosive. Mild edema with violaceous tint, periungual regions, and pinna may be present. Many times, erythema develops in a perifollicular array. Erythema lessens if it is managed or treated, leading to desquamation and postinflammatory hyperpigmentation. If it worsens, macules and papules develop into erythroderma, which is widespread and confluent.
Then, there are subepidermal bullae, particularly at pressure or trauma sites, palms, or soles, and a positive Nikolsky sign (skin that peels off when gently pressed). In patients with chronic GVHD, there may be confluent patches of dermal sclerosis with overlaying scale resembling scleroderma, primarily on the trunk, buttocks, hips, and thighs, and/or flat-topped (lichen planus–like) papules of violaceous color, initially on distal extremities but subsequently widespread. Severe generalized sclerodermoid alterations with necrosis and ulceration on acral and pressure sites also involve the face in cases of more severe disease.
The differential comprises erythroderma, toxic epidermal necrosis, viral exanthem, and exanthematous medication response.
PUVA, extracorporeal photopheresis, or topical glucocorticoids can be used to treat lesions. Methylprednisolone, tacrolimus, cyclosporine, mycophenolate mofetil, etanercept, and infliximab are used to treat systemic effects and rejection.
The entirety of organ failure brought on by histoincompatible, immunocompetent donor cells attacking immunocompetent host tissues is known as graft-versus-host disease (GVHD). A particular organ's expression of GVHD is known as graft-versus-host reaction (GVHR) (e.g., cutaneous GVHR). Usually happening 10–30 days following bone marrow transplantation (BMT), acute cutaneous GVHR ensues. It is the most common and earliest. After liver and other gastrointestinal transplants, GVHR are also frequently observed. Chronic cutaneous GVHR presents as lichenoid and sclerodermoid alterations and happens more than 60 days following allogeneic BMT.
Localized or widespread pruritus, discomfort upon pressure, nausea, vomiting, stomach pain, watery diarrhea, and jaundice are some of the symptoms of acute GVHR.
First, the hands, feet, and upper trunk all develop small, distinct macules and/or papules, particularly on the palms and soles. On the face, macules confluence and are frequently painful and erosive. Mild edema with violaceous tint, periungual regions, and pinna may be present. Many times, erythema develops in a perifollicular array. Erythema lessens if it is managed or treated, leading to desquamation and postinflammatory hyperpigmentation. If it worsens, macules and papules develop into erythroderma, which is widespread and confluent.
Then, there are subepidermal bullae, particularly at pressure or trauma sites, palms, or soles, and a positive Nikolsky sign (skin that peels off when gently pressed). In patients with chronic GVHD, there may be confluent patches of dermal sclerosis with overlaying scale resembling scleroderma, primarily on the trunk, buttocks, hips, and thighs, and/or flat-topped (lichen planus–like) papules of violaceous color, initially on distal extremities but subsequently widespread. Severe generalized sclerodermoid alterations with necrosis and ulceration on acral and pressure sites also involve the face in cases of more severe disease.
The differential comprises erythroderma, toxic epidermal necrosis, viral exanthem, and exanthematous medication response.
PUVA, extracorporeal photopheresis, or topical glucocorticoids can be used to treat lesions. Methylprednisolone, tacrolimus, cyclosporine, mycophenolate mofetil, etanercept, and infliximab are used to treat systemic effects and rejection.
